Abstract
18 patients with malignant teratoma each received VP 16 in combination with cyclophosphamide and actinomycin D, and 7 patients with gestational choriocarcinoma recieved VP 16 alone. VP16 (100mg/m2) was administered on 5 consecutive days as an i.v. infusion of 30 minutes. Blood samples were taken immediately before and after infusion. Serum concentrations of the drug were measured by HPLC and are shown below.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAuthor information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Brindley, C.J., Antoniw, P., Newlands, E.S., Bagshawe, K.D. (1984). Pharmacokinetics and Toxicity of VP 16 (Etoposide) in Patients with Gestational Choriocarcinoma and Malignant Teratoma. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_120
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3837-6_120
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3839-0
Online ISBN: 978-1-4613-3837-6
eBook Packages: Springer Book Archive